Featured Press Releases

Niagen Bioscience

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Are Now Available at Over 50 iCRYO Clinics and More Than 900 Clinics Nationwide

Clover Begins Phase 2 Clinical Evaluation of a Combination Respiratory Vaccine Targeting RSV, hMPV, and ± PIV3

Clover Begins Phase 2 Clinical Evaluation of a Combination Respiratory Vaccine Targeting RSV, hMPV, and ± PIV3

  • 12 Jan 2026

 Clover Biopharmaceuticals, Ltd. a global commercial-stage biotechnology company committed to...

Long Island University alumnus Dr. Howard Murad

Long Island University alumnus Dr. Howard Murad '62 launches the Inclusive Wellness Initiative with the Arnold & Marie Schwartz College of Pharmacy and Health Sciences

Precision BioSciences announces a U.S. patent covering PBGENE-HBV for chronic hepatitis B and provides updates on the program

Precision BioSciences announces a U.S. patent covering PBGENE-HBV for chronic hepatitis B and provides updates on the program's status

Medicines Discovery Catapult and Crown Bioscience form a global alliance for radiopharmaceutical innovation

Medicines Discovery Catapult and Crown Bioscience form a global alliance for radiopharmaceutical innovation

OCuSOFT Inc. introduces Retaine® Omega Forté™, a liquid supplement designed to deliver superior nutritional support in the management of dry eye

OCuSOFT Inc. introduces Retaine® Omega Forté™, a liquid supplement designed to deliver superior nutritional support in the management of dry eye

Niagen Bioscience Launched Niagen™ Plus Liquid At-Home Injections to Support Its Telehealth Expansion

Niagen Bioscience Launched Niagen™ Plus Liquid At-Home Injections to Support Its Telehealth Expansion

  • Niagen Bioscience, Inc
  • 23 Oct 2026
Aptar Appoints Pharma Packaging Veteran Virginie Maes as President of its Pharma Business

Aptar Appoints Pharma Packaging Veteran Virginie Maes as President of its Pharma Business

  • AptarGroup, Inc.
  • 22 Oct 2026
Zai Lab Reports High Response Rates, Encouraging Durability, and a Favorable Safety Profile for Zocilurtatug Pelitecan (Zoci; Formerly ZL-1310) in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab Reports High Response Rates, Encouraging Durability, and a Favorable Safety Profile for Zocilurtatug Pelitecan (Zoci; Formerly ZL-1310) in First-Line Extensive-Stage Small Cell Lung Cancer

  • Zai Lab Limited
  • 22 Oct 2026
Niagen Bioscience Establishes Skincare as a Permanent Tru Niagen® Category with the Launch of Dermatologist-Tested Niagen NanoCloud™ as a Core Product

Niagen Bioscience Establishes Skincare as a Permanent Tru Niagen® Category with the Launch of Dermatologist-Tested Niagen NanoCloud™ as a Core Product

  • Niagen Bioscience, Inc
  • 20 Oct 2026
BD Strengthens Peripheral Vascular Innovation Leadership with Positive AGILITY Trial Results

BD Strengthens Peripheral Vascular Innovation Leadership with Positive AGILITY Trial Results

  • BD
  • 08 Oct 2026
The meeting will focus on Nordic Pharma, Inc.’s patient data and study results on LACRIFILL® Canalicular Gel, a novel ocular surface therapy

The meeting will focus on Nordic Pharma, Inc.’s patient data and study results on LACRIFILL® Canalicular Gel, a novel ocular surface therapy

  • Nordic Pharma, Inc.
  • 08 Oct 2026

Most Popular
October   2026
M T W T F S S
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.